- Home
- NVMI vs IONS Comparison
NVMI vs IONS Comparison
Compare NVMI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVMI
- IONS
- Stock Information
- Founded
- NVMI 1993
- IONS 1989
- Country
- NVMI Israel
- IONS United States
- Employees
- NVMI N/A
- IONS N/A
- Industry
- NVMI Electronic Components
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- NVMI Technology
- IONS Health Care
- Exchange
- NVMI Nasdaq
- IONS Nasdaq
- Market Cap
- NVMI 6.9B
- IONS 6.8B
- IPO Year
- NVMI 2000
- IONS 1991
- Fundamental
- Price
- NVMI $330.65
- IONS $69.25
- Analyst Decision
- NVMI Strong Buy
- IONS Strong Buy
- Analyst Count
- NVMI 5
- IONS 18
- Target Price
- NVMI $282.50
- IONS $72.83
- AVG Volume (30 Days)
- NVMI 494.5K
- IONS 2.2M
- Earning Date
- NVMI 11-06-2025
- IONS 11-05-2025
- Dividend Yield
- NVMI N/A
- IONS N/A
- EPS Growth
- NVMI 52.61
- IONS N/A
- EPS
- NVMI 7.36
- IONS N/A
- Revenue
- NVMI $807,085,000.00
- IONS $944,050,000.00
- Revenue This Year
- NVMI $32.37
- IONS $24.01
- Revenue Next Year
- NVMI $7.30
- IONS $4.06
- P/E Ratio
- NVMI $43.74
- IONS N/A
- Revenue Growth
- NVMI 43.69
- IONS 16.05
- 52 Week Low
- NVMI $154.00
- IONS $23.95
- 52 Week High
- NVMI $336.78
- IONS $69.25
- Technical
- Relative Strength Index (RSI)
- NVMI 69.30
- IONS 81.27
- Support Level
- NVMI $319.08
- IONS $61.03
- Resistance Level
- NVMI $336.78
- IONS $63.18
- Average True Range (ATR)
- NVMI 10.66
- IONS 1.63
- MACD
- NVMI 1.40
- IONS 0.07
- Stochastic Oscillator
- NVMI 90.27
- IONS 97.28
About NVMI Nova Ltd.
Nova Ltd is a semiconductor equipment manufacturer. The company provides metrology solutions for process control used in semiconductor manufacturing. The company offers in-line optical and x-ray stand-alone metrology systems, as well as integrated optical metrology systems. The product range consists of Nova 2040, Nova 3090Next, Nova i500 and i500 Plus, Nova T500, Nova T600, Nova V2600, HelioSense 100, Nova Hybrid Metrology solution, NovaMars. The company generates the majority of its revenue from China. Geographically the company has its business spread across the region of Taiwan, Korea, China, the United States, and Europe.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.